Non-Small Cell Lung Cancer

The KEYNOTE B36 study is a Phase 2 pilot, single-arm, open-label study designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T. Study patients use the device concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer (NSCLC).